Videos

Explore how BTK resistance drives poor outcomes in relapsed mantle cell lymphoma and why ZUMA-2 CAR T therapy emerges as a game-changing option.

Dr Saba emphasizes the prioritizing of rapid BRAF testing and surgical assessment in ATC workups.

Rashmi Chugh, MD, discusses the early outcomes of a trial of ozekibart plus chemotherapy in Ewing sarcoma.

Dr Raj Singh discusses radiation strategies, dose escalation, PCI debates, and multidisciplinary collaboration in small cell lung cancer management.

Dr. Costa concludes by emphasizing the transformative moment in multiple myeloma therapy, with rapidly increasing agents demonstrating incredible efficacy alongside accelerated newer class development.

ASCO's updated thyroid cancer guidelines help clinicians navigate rapidly evolving systemic therapies, from VEGF inhibitors to BRAF-targeted agents.

Rashmi Chugh, MD, describes the background for a study of ozekibart in Ewing sarcoma.

Learn how myeloma experts sequence CAR T and bispecifics, boost MRD-negative rates, and why academic-community teamwork improves outcomes.

Clinical trials show subcutaneous isatuximab is preferred by patients, enabling faster dosing, home treatment, and paving the way for future self-administration.

Dr Bazhenova presents TRUST data at AACR 2026, showing taletrectinib reached a 46.1-month PFS and 89.8% ORR in TKI-naive, ROS1-positive metastatic NSCLC.

In this segment on advanced renal cell carcinoma, Dr. Geynisman focuses on the clinical scenarios in which cabozantinib is selected following progression on first-line therapy.

In this segment on advanced renal cell carcinoma, Dr. Wulff transitions the discussion to treatment sequencing after progression on first-line IO-based therapy.

Liquid biopsy ctDNA reveals targets and flags residual disease in esophageal and gastric cancers, hinting at earlier relapse detection and tailored care.

Dr Christine Bestvina discusses EGFR treatment shifts, expanding community clinical trial access, and upcoming KRAS G12C and neoadjuvant therapy data.

On-body injector isatuximab enables at-home myeloma treatment, cutting infusion visits, easing time and financial strain, and expanding access for rural patients.

On-body isatuximab injection matches IV results in relapsed multiple myeloma, with similar safety, drug levels, and better convenience.

Discover ways to detect early-onset cancers sooner, avoid age bias, and coordinate multidisciplinary care, fertility, genetics, and support.

Matthew Powell, MD, discusses long-term overall survival results with dostarlimab plus chemo in dMMR endometrial cancer patients from the RUBY trial.

MSK researchers found that BRCA2 mutations lower the barrier for RB1 loss, causing CDK4/6 inhibitor resistance.

New targeted therapies reshape biliary tract cancer care, highlighting FGFR2/IDH1, HER2 and KRAS options plus smarter second-line sequencing.

Dr. Costa discusses evolution from initial single-arm bispecific experience in heavily pretreated patients to recent earlier-setting data.

Dr. Costa addresses community-based versus academic center care debates for complex patients requiring multiple therapy lines.

At SGO 2026, Alison Schram, MD, highlighted first-in-class tumor suppressor reactivation and emphasized early NGS testing in ovarian cancer.

Bradley Monk, MD, discusses the KEYNOTE-B96 trial in which pembrolizumab plus paclitaxel +/- bevacizumab improved OS in platinum-resistant ovarian cancer.

MSK experts discuss FLAURA2 updates, emerging targets in mesothelioma, and next-gen immunotherapies from the 2026 European Lung Cancer Congress.

BCMA bispecifics in relapsed myeloma deliver 60–70% responses and year-long PFS, expanding options beyond limited CAR T access.

BCMA bispecifics boost relapsed myeloma responses to 60–70% and extend PFS to 12–18 months, offering durable options beyond CAR-T.

HER2-targeted ADCs show ~50% response rates in pretreated endometrial cancer, with durable responses and manageable safety profiles per 2026 SGO data.

Pancreatic cancer research tackles treatment resistance with targeted drug delivery, immune-boosting combinations, and smarter therapy pairings to extend responses in trials.

Lilit Karapetyan, MD, MS, discusses how a single-center trial suggests patients with poorer performance status could be eligible for tumor-infiltrating lymphocyte therapy.